Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 10:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 116 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Bird Flu Clear all
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Tolerability Study of GlaxoSmithKline (GSK)1557484A Vaccine in Adults at Occupational Risk for Influenza A (H5N1) Exposure

NCT01788228
View directory record Official record
Conditions
Influenza, Influenza Vaccines
Interventions
Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia)
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
3
States / cities
Stockbridge, Georgia • Rockville, Maryland • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 23, 2020 · Synced Oct 31, 2026, 10:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety and Immunogenicity of Two Doses of a Novel H5 Central Antigen mRNA-LNP in Healthy Adults

NCT07019883
View directory record Official record
Conditions
Avian Influenza
Interventions
H5 AC-Anhui RNA Vaccine, H5 Astrakhan RNA Vaccine, Sodium Chloride, 0.9%
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
3
States / cities
Durham, North Carolina • Nashville, Tennessee • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 31, 2026, 10:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Immunogenicity of VAL-339851 in Healthy Adult Subjects

NCT03345043
View directory record Official record
Conditions
Influenza
Interventions
VAL-339851, Placebo
Biological · Other
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 49 Years
Enrollment
156 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Oct 31, 2026, 10:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Different Formulations of an Intramuscular A/H5N1 Inactivated, Split Virion Influenza Adjuvanted Vaccine

NCT00664417
View directory record Official record
Conditions
Influenza, Orthomyxoviridae Infections
Interventions
Monovalent subvirion H5N1 influenza vaccine, Physiological saline
Biological
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 40 Years
Enrollment
375 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
6
States / cities
San Diego, California • South Miami, Florida • Springfield, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2012 · Synced Oct 31, 2026, 10:38 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged ≥18 Years

NCT00719043
View directory record Official record
Conditions
Influenza
Interventions
A/turkey H5N1 vaccine, Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia), Placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
841 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
10
States / cities
Denver, Colorado • Chicago, Illinois • Metairie, Louisiana + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2018 · Synced Oct 31, 2026, 10:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety Study of Inactivated Subunit H5N1 Influenza Vaccine in Prior Recipients of Live Attenuated H2N2, H6N1 and H9N2 Influenza Vaccines and in H5N1 and Live Attenuated Vaccine Naïve Individuals

NCT03816878
View directory record Official record
Conditions
Influenza
Interventions
H5N1 pISV
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Oct 31, 2026, 10:38 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Open-Label Study of H5 Vaccine in Participants of Protocol 04-077

NCT00402649
View directory record Official record
Conditions
Influenza
Interventions
Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 10 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
3
States / cities
Torrance, California • Baltimore, Maryland • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 13, 2011 · Synced Oct 31, 2026, 10:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immune Response to an H5N1 Influenza Vaccine in People Who Have Previously Received an H5N1 or H7N3 Influenza Vaccine and in People Who Have Never Received a Live Attenuated Influenza Vaccine

NCT01443663
View directory record Official record
Conditions
H5N1 Influenza
Interventions
H5N1 Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
22 Years to 54 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 9, 2016 · Synced Oct 31, 2026, 10:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Cellular and Humoral Immune Response to Primary and Secondary Immunization With Subvirion H5N1 Vaccines

NCT01086566
View directory record Official record
Conditions
Influenza
Interventions
Influenza Virus Vaccine, Monovalent A/H5N1 A/Indonesia/05/2005
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jan 1, 2016 · Synced Oct 31, 2026, 10:38 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Inactivated Influenza A/H5N1 Vaccine in the Elderly

NCT00230750
View directory record Official record
Conditions
Influenza
Interventions
Influenza A/H5N1 Vaccine, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
65 Years and older
Enrollment
261 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
4
States / cities
Torrance, California • Rochester, New York • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2013 · Synced Oct 31, 2026, 10:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Group Study of the Safety of and Immune Response to a Bird Flu Virus Vaccine (H5N1) in Healthy Adults

NCT00488046
View directory record Official record
Conditions
Influenza, Virus Diseases
Interventions
H5N1 (6-2) AA ca Recombinant (A/Hong Kong/213/2003 x A/AnnArbor/6/60 ca)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 20, 2007 · Synced Oct 31, 2026, 10:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Dose-finding Study of Four Dosage Levels of an H7N9 Influenza Vaccine in Adults Between Ages of 18 Years and 65 Years

NCT01928472
View directory record Official record
Conditions
H7N9 Influenza
Interventions
H7N9c low dose with adjuvant, H7N9c medium dose with adjuvant, H7N9c high dose with adjuvant, H7N9c high dose without adjuvant
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
18 Years to 64 Years
Enrollment
402 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
6
States / cities
San Diego, California • Melbourne, Florida • Peoria, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2019 · Synced Oct 31, 2026, 10:38 AM EDT
Completed Phase 1 Interventional

Phase I Open-Label Study of Recombinant DNA Plasmid Vaccine, VRC-AVIDNA036-00-VP, Encoding for Influenza Virus H5 Hemagglutinin Protein Given Intradermally

NCT00489931
View directory record Official record
Conditions
Influenza A Virus, H5N1 Subtype, Influenza A Virus, Influenzavirus A, Orthomyxovirdae, H5N1 Virus
Interventions
VRC-AVIDNA036-00-VP
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 31, 2026, 10:38 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Systems Biology of Influenza A (H5N1) Virus Monovalent Vaccine With and Without Adjuvant System 03 (AS03)

NCT01910519
View directory record Official record
Conditions
Influenza A Virus, H5N1 Subtype
Interventions
H5N1 vaccine plus AS03 adjuvant, H5N1 vaccine without adjuvant
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
21 Years to 45 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 12, 2019 · Synced Oct 31, 2026, 10:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dose-Escalating Trial Using Vero Cell-culture Derived H5N1 +/- Aluminum in Adults

NCT00382980
View directory record Official record
Conditions
Influenza
Interventions
Aluminum hydroxide, Inactivated Vero cell based whole virus influenza A/H5N1, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
308 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
5
States / cities
Stanford, California • Torrance, California • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2010 · Synced Oct 31, 2026, 10:38 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

St. Jude Open Label H5 Trial

NCT00311675
View directory record Official record
Conditions
Influenza
Interventions
Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 27, 2010 · Synced Oct 31, 2026, 10:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

H5N1 Mix and Match With MF59

NCT01317745
View directory record Official record
Conditions
Influenza
Interventions
Phosphate Buffered Saline (PBS) diluent, MF59 Adjuvant, H5N1 Antigen
Other · Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
270 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
5
States / cities
Atlanta, Georgia • Decatur, Georgia • Iowa City, Iowa + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2013 · Synced Oct 31, 2026, 10:38 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

H7N9 Boost in Healthy Adults

NCT02586792
View directory record Official record
Conditions
Influenza
Interventions
Monovalent influenza A/H7N9 virus vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
19 Years to 50 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 22, 2018 · Synced Oct 31, 2026, 10:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of an Oral Vaccine to Prevent Avian Influenza

NCT01335347
View directory record Official record
Conditions
Avian Influenza, Bird Flu
Interventions
ND1.1, Placebo control
Biological
Lead sponsor
Vaxart
Industry
Eligibility
18 Years to 49 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Oct 31, 2026, 10:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study of a H5N1 Influenza Vaccine (Reverse Genetic Reassortant)

NCT00783926
View directory record Official record
Conditions
Influenza, Pandemic Influenza
Interventions
H5N1 Influenza Vaccine, Whole virion, Vero cell-derived, Inactivated Influenza Vaccine, non-adjuvanted (reverse genetic reassortant/H5N1 hemagglutinin antigen)
Biological
Lead sponsor
Alachua Government Services, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
422 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
6
States / cities
Wichita, Kansas • Lexington, Kentucky • Kansas City, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2015 · Synced Oct 31, 2026, 10:38 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Open Label Evaluation of H5N1 Vaccine at Vaccine Manufacturing Facilities

NCT00311649
View directory record Official record
Conditions
Influenza
Interventions
Inactivated Influenza A Vaccine A/H5N1
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Swiftwater, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 12, 2011 · Synced Oct 31, 2026, 10:38 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Higher Dose Intradermal H5 Vaccine

NCT00439335
View directory record Official record
Conditions
Influenza
Interventions
Inactivated Influenza A Vaccine A/H5N1, Placebo (IM), Placebo (ID)
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
227 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 9, 2013 · Synced Oct 31, 2026, 10:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity Study of Adenovirus-vectored, Intranasal Pandemic Influenza Vaccine.

NCT00755703
View directory record Official record
Conditions
Influenza A Subtype H5N1 Infection
Interventions
Pandemic Influenza Vaccine, Placebo
Biological
Lead sponsor
Altimmune, Inc.
Industry
Eligibility
19 Years to 49 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Oct 31, 2026, 10:38 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Study to Evaluate Safety and Immunogenicity of Different Priming and Booster Regimens With Adjuvanted H5N8 and/or H5N6 Influenza Vaccine in Adults

NCT05874713
View directory record Official record
Conditions
Influenza, Human, Infections, Respiratory Tract Infections, Virus Diseases, Infection Viral
Interventions
aH5N8c on Day 1, aH5N6c on Day 1, aH5N8c on Day 22, aH5N6c on Day 22, aH5N8c on Day 202
Biological
Lead sponsor
Seqirus
Industry
Eligibility
18 Years and older
Enrollment
480 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
9
States / cities
Cullman, Alabama • Lilburn, Georgia • Norcross, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2024 · Synced Oct 31, 2026, 10:38 AM EDT